Pacira Biosciences (PCRX) said Tuesday it has received clearance from the US Food & Drug Administration to market a new Smart Tip designed to access the medial branch nerves to manage chronic low back pain.
The iovera system relieves pain via cryoneurolysis -- a process whereby focused cold therapy is applied to a targeted nerve, temporarily interrupting its ability to transmit pain signals, the company said.
The stock is up about 1.8% in recent trading.
Price: 18.96, Change: +0.33, Percent Change: +1.77
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.